Last updated on January 2018

A Randomized, Double-blind, Vehicle-controlled Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects with Alopecia Universalis and Alopecia Totalis

Brief description of study

The objective of this study is to assess the safety tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution, 0.46% compared to vehicle in subjects with alopecia universalis (AU) and alopecia totalis (AT) over the course of one month of continuous daily use.

Clinical Study Identifier: TX155471

Contact Investigators or Research Sites near you

Start Over

Monica Serra

Sadick Research Group
New York, NY USA
  Connect »